Explore › Outcome › overall survival
Outcome

overall survival

Also known as: 3-year overall survival overall survival overall survival and complete remission duration overall survival stratified by MRD status OS CRD CR
24 findings 3 papers 16 related entities View in graph →

Related entities

interventions
Augmented Berlin–Frankfurt–Münster (ABFM) pediatric-based chemotherapy regimen1 Minimal Residual Disease1 Intrathecal chemotherapy1 Intrathecal consolidation chemotherapy1 Timing of stage1 International neuroblastoma pathology classification: Favorable histology group, patient age 1.5 years up to but less than 5 years, with differentiating neuroblastoma (Schwannian stroma-poor), and low mitosis-karyorrhexis index1 CNS leukemia response to treatment1 bridging chemotherapy1
conditions
Central nervous system5 Acute lymphoblastic leukemia2 Precursor B-cell acute lymphoblastic leukemia in remission1
populations
Adolescents2 Children1
studys
PMC87117235 PMC55588532 PMC93613931

Findings (50)

None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease

Effect: decline; HR 3.73; CI: 95% CI: 1.39-9.97

Size: HR 3.73 CI: 95% CI: 1.39-9.97
PMC9361393
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →
None
decline

Pediatric patients with CNS leukemia had significantly better 3-year overall survival compared to adult patients, though the likelihood of achieving CNS complete remission was not significantly differ

Effect: decline; 81% vs. 28%

Size: 81% vs. 28%
PMC8711723
Finding details → · Paper → · Graph →

Papers (3)